Loading
Life sciences · Journal article
Frontiers in Cellular and Infection Microbiology · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Persistent high-risk human papillomavirus (HR-HPV) infection is necessary but not sufficient for cervical cancer, which caused approximately 350,000 deaths in 2022. Co-infections with Chlamydia trachomatis (CT), herpes simplex virus type 2 (HSV-2), and HIV may modify cervical carcinogenesis, but causal inference is constrained by confounding, study heterogeneity, and limited mechanistic validation in human tissue. This systematic integrative review (PRISMA 2020) searched PubMed, Embase, Scopus, Web of Science, and the Cochrane Library (January 2015 to March 2026); risk of bias was assessed using the Newcastle-Ottawa Scale and ROBINS-I, and certainty of evidence using GRADE. HIV co-infection shows the strongest evidence: approximately 6-fold risk elevation, a confirmed CD4 dose-response, and residual risk that persists despite antiretroviral therapy (GRADE: high). CT is associated with 2-4-fold elevations in observational studies, but substantial heterogeneity, residual sexual-behavior confounding, funnel-plot asymmetry suggesting publication bias, and attenuation of the HPV-adjusted independent effect (OR 1.76, 95% CI 1.03-3.01) leave causality uncertain (GRADE: Low-Moderate). HSV-2 associations are inconsistent: pooled cervical cancer risk was elevated (OR 3.01, 95% CI 2.24-4.04), but most estimates were unadjusted for HPV status, prospective studies are non-significant, and mechanistic evidence derives from non-human models (GRADE: low). A context-dependent syndemic effect appears in HIV co-infected populations. In conclusion, HIV meets criteria for a probable causal modifier of HPV-driven carcinogenesis, supporting WHO-endorsed intensified screening for women living with HIV; CT’s role remains uncertain pending rigorous confounder control; and HSV-2 does not meet the threshold for independent co-factor classification. Priorities include prospective cohorts and human cervical-tissue mechanistic validation.